Mechanism for the prevention of cholestasis involving cytochrome P4503A overexpression

Journal of Investigative Medicine

Volumn 48, Issue 1, 2000, Pages 49-59

  Paolini, Moreno ^b   Pozzetti, Laura ^b   Piazza, Francesco ^b   Guerra, Maria Clelia ^b   Speroni, Ester ^b   Cantelli Forti, Giorgio ^b   Roda, Aldo ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b NONE

Author keywords

Cytochrome P450; Liver cholestasis; P glycoprotein; Taurochenodeoxycholic acid; Taurohyodeoxycholic acid

Indexed keywords

AMINOPYRINE N DEMETHYLASE; CYTOCHROME P450 3A; CYTOCHROME P450 REDUCTASE; GLYCOPROTEIN P; HYODEOXYCHOLIC ACID; LIVER PROTECTIVE AGENT; TAUROCHENODEOXYCHOLIC ACID; TESTOSTERONE; VINBLASTINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BILE FLOW; BILIARY EXCRETION; CELL FRACTIONATION; CHOLESTASIS; CONTROLLED STUDY; ENZYME INDUCTION; GENE OVEREXPRESSION; LIVER MICROSOME; LIVER PROTECTION; LIVER TOXICITY; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT;

ANIMALIA; STAPHYLOCOCCUS PHAGE 3A;

EID: 0033940813     PISSN: 17088267     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Roda A, Piazza F, Baraldini M, Speroni E, Guerra MC, Cerr C, Cantelli-Forti G. Taurohyodeoxycholic acid protects against taurochenodeoxycholic acid-induced cholestasis in the rat. Hepatology 1998;27: 520-5.
2. Kitani K, Ohta M, Kanai S. Tauroursodeoxycholate prevents biliary protein excretion induced by other bile salts in the rat. Am J Physiol 1985;248:G407-G417.
3. Kitani K, Kanai S, Sato Y, Ohta M. Tauro α-muricholate is as effective as Tauro β-muricholate and tauroursodeoxycholate in preventing the hepatocyte damage caused by continuous infusion of taurochenodeoxycholate in the rat. Hepatology 1994;19:1011-12.
4. Kanai S, Kitani K. Glycoursodeoxycholate is as effective as taurochenodeoxycholate in preventing the taurocholate-induced cholestasis in the rat. Res Commun Chem Pathol Pharmacol 1983;42:423-30.
5. Roda A, Pellicciari R, Polimeni C, Cerré C, Cantelli Forti G, Sadeghpour B, Sapigni E, et al. Metabolism, pharmacokinetics, and activity of a new 6-fluoro analogue of ursodeoxycholic acid in rats and hamsters. Gastroenterology 1995;108:1204-14.
6. Roda A, Cerré C, Manetta AC, Cainelli G, Umani-Ronchi A, Panunzio M. Synthesis and physicochemical, biological and pharmacological properties of new bile acids amidated with cyclic amino acids. J Med Chem 1996;39:2270-6.
7. Roda A, Hofmann AF, Mysels KJ. The influence of bile salt structure on self association in aqueous solutions. J Biol Chem 1983; 258:6362-70.
8. Roda A, Minutello A, Angelotti MA, Fini A. Bile acids structure-activity relationship: evaluation of bile acid lipophilicity using 1-octanol/ water partition coefficient and reverse phase HPLC. J Lipid Res 1990; 31:1433-43.
9. Kitani K, Kanai S, Ohhta M. Tauroursodeoxycholate prevents taurocholate-induced cholestasis in the rat. Life Sci 1982;30:515-23.
10. 2+ activity of isolated rat hepatocytes. Hepatology 1988;8:887-91.
11. 2+ release from permeabilized liver cells and liver microsomes. J Biol Chem 1989;264:157-67.
12. Schmucker DL, Ohta M, Kanai S, Sato Y, Kitani K. Hepatic injury induced by bile salts: correlation between biochemical and morphological events. Hepatology 1990;12:1216-21.
13. Ward A, Brogden AN, Heel RC, Speight TM, Avery GS. Ursodeoxycholic acid: a review of its pharmacological properties and therapeutic efficacy. Drugs 1984;27:95-131.
14. Kaplan MM, Righetti A. Induction of rat liver alkaline phosphatase: the mechanism of the serum elevation in bile duct obstruction. J Clin Invest 1970;49:508-16.
15. Kaplan MM, Onkubo A, Quaroni EG, Sze-Tu D. Increased synthesis of rat liver alkaline phosphatase by bile duct ligation. Hepatology 1983;3:433-9.
16. Gurantz D, Schteingart CD, Hagey LR, Steinbach JH, Grotmol T, Hofmann AF. Hypercholeresis induced by unconjugated bile acids infusion correlates with recovery in bile of unconjugated bile acids. Hepatology 1991;13:340-50.
17. Salphati L, Bernet LZ. Modulation of P-glycoprotein expression by cytochrome P450 inducers in male and female rat livers. Biochemical Pharmacol 1998;55:387-95.
18. Gottesman MM, Pastan I. Biochemistry of multidrug resistence mediated by the multidrug transporter. Annu Rev Biochem 1993;62: 385-427.
19. Chin KV, Pastan I, Gottesman MM. Function and regulation of the human multidrug transporter. Adv Cancer Res 1993;60:157-80.
20. Leveille WC, Arias IM. The biology of the P-glycoproteins. J Membr Biol 1995;143:89-102.
21. Borst P, Schinkel AH, Smit JJ, Wagenaar E, Van Deemter L, Smith AJ, Eijdems EW, Baas F, Zaman GJ. Classical and novel forms of multidrug resistence and the physiological functions of P-glycoproteins in mammals. Pharmacol Ther 1993;60:289-99.
22. Ueda K, Okamura N, Hirai M, Tanigawara Y, Saeki T, Kioka N, Komano T, Hori R. Human P-glycoprotein transports cortisol, aldosterone and dexamethasone, but not progesterone. J Biol Chem 1992;267: 24248-52.
23. Ford JM, Hait WN. Pharmacologic circumvention of multidrug resistance. Cytotechnology 1993;12:171-212.
24. Devault A, Gros P. Two members of the mouse mdr gene family confer multidrug resistence with overlapping but distinct drug specificities. Mol Cell Biol 1990;19:1652-63.
25. Gerloff T, Stieger B, Hagenbuch B, Madon J, Landmann L, Roth J, Hofmann AF, Meier P. The sister of P-glycoprotein represents the canalicular bile salt export pump of mammalian liver. J Biol Chem 1998;273:10046-50.
26. Accatino L, Pizarro M, Solis N, Koenig CS, Vollrath V, Chianale J. Modulation of hepatic content and biliary excretion of P-glycoprotein in hepatocellular and obstructive cholestasis in rat. J Hepatol 1996;25: 349-61.
27. Smit WJ, Duin E, Steen H, Oosting R, Roggeveld J, Meijer DKF. Interactions between P-glycoprotein substrates and other cationic drugs at the hepatic excretory level. Br J Pharm 1998;123:361-70.
28. Paolini M, Pozzetti L, Pedulli GF, Cipolloni M, Mesirca R., Cantelli-Forti G. Paramagnetic resonance in detecting carcinogenic risk from cytochrome P450 overexpression. J Investig Med 1996;44:470-3.
29. . Paolini M, Barone M, Corsi C, Paganin C, Revoltella RP. Expression and inducibility of drug-metabolising enzymes in novel murine liver epithelial cell lines and their ability to activate procarcinogens. Cancer Res 1991;51:301-9.
30. Mazel P. Fundamentals of drug metabolism and drug disposition. Lado B, Mahdel HG, Way EL, eds. Baltimore: Williams and Wilkins, 1971:546-50.
31. Nash T. Colorimetric estimation of formaldehyde by means of Hantzsch reaction. Biochem J 1953;55:416-21.
32. Paolini M, Mesirca R, Pozzetti L, Sapone A, Cantelli-Forti G. Induction of CYP 2B1 mediated pentoxyresorufin O-dealkylase activity in different species, sex and tissue by prototype 2B1-inducers. Chem Biol Interact 1995;95:127-39.
33. Platt J, Molitor E, Doehmer I, Dogra S, Oesch F. Genetically engineered V79 Chinese hamster cell. Expression of purified cytochrome P4502B1 monooxygenase activity. Biochem Toxicol 1989;4:1-5.
34. Van der Hoeven TH. Assay of hepatic microsomal testosterone hydroxylases by high-performance liquid chromatography. Anal Biochem 1984;138:57-65.
35. Paolini M, Pozzetti L, Sapone A, Biagi GL, Cantelli-Forti G. Development of basal and induced testosterone hydroxylase activity in the chicken embryo in ovo. Br J Pharmacol 1997:;22:344-50.
36. Chung WA, Cha YN. Oxidation of caffeine to theobromine and theophillyne is catalyzed primarily by flavin-containing monooxygenase in liver microsomes. Biochem Biophys Res Comm 1997;235:685-8.
37. Lowry OH, Rosenbrough HJ, Fair AL, Randall RJ. Protein measurement with folin phenol reagent. J Biol Chem 1951;193:265-75.
38. Bailey YL. Techniques in protein chemistry. Amsterdam: Elsevier, 1967:340-1.
39. Box GEP, Hunter WG. Statistics for experiments. Wiley: New York, 1978: 80-82.
40. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680-5.
41. Towbin H, Stachelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sei USA 1979;76:4350-4.
42. Dutton DR, Reed GA, Parkinson A. Redox cycling of resorufin catalyzed by rat liver microsomal NADPH-cytochrome P450 reductase. Arch Biochem Biophys 1989;268:605-16.
43. Fausa O. Quantitative determination of serum bile acids using a purified 3α dehydrogenase. Scand J Gastroenterol 1975;10:747-51.
44. Roda A, Festi D, Sama C, Mazzella G, Aldini R, Roda E, Barbara L. Enzymatic determination of cholesterol in bile. Clin Chim Acta 1975;64:337-41.
45. Roda A, Germiniani S, Rossi R, Festi D, Roda E, Barbara L. Enzymatic determination of phospholipids in bile. Lab J Res Med 1981; 2:119-22.
46. Rossi SS, Converse JL, Hofmann AF. High pressure liquid chromatographic analysis of conjugated bile acids in human bile: simultaneous resolution of sulfated and unsulfated lithocholyl amidates and the common conjugated bile acids. J Lipid Res 1987;28:589-95.
47. Roda A, Gioacchini AM, Cerré C, Baraldini M. High-performance liquid chromatographic-electrospray mass spectrometric analysis of bile acids in biological fluids. J Chromatogr 1995;665: 281-94.
48. Loria P, Bozzoli M, Angelico M, Bertolotti M, Carubbi F, Concari M, Baiocchi L, et al. Effect of taurohyodeoxycholic acid on biliary lipid secretion in man: preliminary report. Ital J Gastroenterol 1996;28:391-2.
49. Shimada T, Yamazake H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994;270:414-23.
50. Watkins PB, Wrighton SA, Schuetz FG, Molowa DT, Guzelian PS. Identification of glucocorticoid-inducible cytochromes P450 in the intestinal mucosa of rats and man. J Clin Invest 1987;80: 1029-36.
51. James P, Whitlock JR, Denison MS. Induction of cytochrome P450 enzymes that metabolize xenobiotics. In: Ortiz de Montellano PR, ed. Cytochrome P450: structure, mechanism, and biochemistry. 2nd ed. New York: Plenum Press, 1995:367.
52. Brown PG, Thorgeirsson SS, Silvermann YA. Cloning and regulation of the rat MDR2 gene. Nucleic Acids Res 1993;21:3885-91.
53. Volm M, Mattern J, Pmmerenke EW. Lime course of mdr gene amplification during in vivo selection for dexorubicin-resistence and during reversed in murine leukemia L1210. Anticancer Res 1991;11: 579-85.
54. Araya Z, Hellman U, Hansson R. Characterisation of taurochenodeoxycholic acid 6 alpha-hydroxylase from pig liver microsomes. Eur J Biochem 1995;231:855-61.
55. Mazzanti R, Fantappié O, Kamimoto Y, Gatmaitan Z, Gentilini P, Arias IM. Bile acid inhibition of P-glycoprotein mediated transport in multidrug resistant cells and rat liver canalicular membrane vesicles. Hepatology 1993;20:170-6.
56. Kamimoto Y, Gatmaitan Z, Hsu J, Arias IM. The function of GP170, the multidrug resistence gene product, in rat liver canalicular membrane vesicles. J Biol Chem 1989;264:11693-8.
57. Erlinger S. Do intracellular organelles have any role in transport of bile acids by hepatocytes? J Hepatol 1996;24(suppl):88-93.
58. Chen J, Farrell GC. Bile acids produce a generalized reduction of the catalytic activity of cytochromes P450 and other hepatic microsomal enzymes in vitro: relevance to drug metabolism in experimental cholestasis. J Gastoenterol Hepatology 1996;11:870-7.